Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can growth hormone or DHEA help women with low egg reserve get pregnant?

NCT ID NCT07323329

Disease control Sponsor: Beni-Suef University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving growth hormone or DHEA (a natural hormone) can improve egg production and pregnancy rates in women with poor ovarian reserve who are undergoing IVF. 165 women will receive one of these treatments or a placebo (folic acid only) for 1-3 months before their IVF cycle. The goal is to see which approach leads to more mature eggs and higher pregnancy rates.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Somatropin (growth hormone) and dehydroepiandrosterone (DHEA)
What this could lead to
If it works, this could offer a way to improve egg quantity and quality in women with poor ovarian reserve, potentially increasing their chances of pregnancy through IVF.
What could go wrong
This is a mid-stage trial with only 165 participants, so results may not apply to everyone. Hormone treatments can have side effects, and success is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 165 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: At least two of the following three criteria had to be present after maximal stimulation: 1. Advanced maternal age (\>40 years) or any other risk factor for Poor Ovarian Response (POR). 2. ≤3 oocytes with a conventional stimulation protocol). 3. An abnormal ovarian reserve test \[i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng/ml\]. Exclusion Criteria: 1. Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes and thyroid dysfunction. 2. Any pelvic pathology such as hydrosalpinx, uterine anomaly. 3. Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility Infertility (ivf patients)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beni-Suef University Hospital

    RECRUITING

    Banī Suwayf, Beni Suweif Governorate, 62521, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.